Format

Send to

Choose Destination
Nat Rev Endocrinol. 2011 Aug 30;7(10):569-80. doi: 10.1038/nrendo.2011.142.

Molecular genetics and diagnosis of thyroid cancer.

Author information

1
Department of Pathology and Laboratory Medicine, University of Pittsburgh School of Medicine, PUH C-606, 200 Lothrop Street, Pittsburgh, PA 15213, USA. nikiforovye@upmc.edu

Abstract

Thyroid cancer is a common type of endocrine malignancy, and its incidence has been steadily increasing in many regions of the world. Initiation and progression of thyroid cancer involves multiple genetic and epigenetic alterations, of which mutations leading to the activation of the MAPK and PI3K-AKT signaling pathways are crucial. Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARĪ³ chromosomal rearrangements. The mutational mechanisms seem to be linked to specific etiologic factors. Chromosomal rearrangements have a strong association with exposure to ionizing radiation and possibly with DNA fragility, whereas point mutations probably arise as a result of chemical mutagenesis. A potential role of dietary iodine excess in the generation of BRAF point mutations has also been proposed. Somatic mutations and other molecular alterations have been recognized as helpful diagnostic and prognostic markers for thyroid cancer and are beginning to be introduced into clinical practice, to offer a valuable tool for the management of patients with thyroid nodules.

PMID:
21878896
DOI:
10.1038/nrendo.2011.142
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center